Navigation Links
Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
Date:4/18/2008

wan-Ganz. Additional company information can be found at http://www.edwards.com.

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements include, but are not limited to, the timing and progress of clinical studies relating to the company's transcatheter valve technologies and the market opportunity for transcatheter technologies. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict.

Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2007.

Edwards, Edwards SAPIEN and RetroFlex are trademarks of Edwards Lifesciences Corporation. Edwards Lifesciences, the stylized E logo, CardioVations, Carpentier-Edwards, Cosgrove-Edwards, FloTrac, Fogarty, PERIMOUNT Magna and Swan-Ganz are trademarks of Edwards Lifesciences Corporation and are registered in the United States Patent and Trademark Office.


'/>"/>
SOURCE Edwards Lifesciences Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edwards Resilient Trial Demonstrates Statistically Superior Results for Treating Peripheral Arterial Disease in the Leg
2. Aida Announces New Anti-Cancer Drug Under Development
3. AlphaVax Announces Initial Analysis of Data From CMV Phase 1 Clinical Trial
4. Tepha Announces First Human Usage of Medical Devices Derived from New Class of Resorbable Polymers
5. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
6. ViroPharma Announces Discontinuation of HCV-796 Development
7. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
8. Free Prostate Cancer Seminar in Lake Ridge, VA: Dr. Charles Snuffy Myers Announces Vitamin D Clinical Trials
9. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
10. Cardiums Innercool Therapies Unit Announces Publication of Positive Effects of Early and Rapid Hypothermia Following Heart Attack
11. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...Netherlands and JOHANNESBURG, November 25 /PRNewsw...and Pyxis Discovery announced today,that they have...t both,companies, services. , Pyxis,s wor...y expertise,will be coupled with iThemba,s service...stry support to projects identified through Pyxis,...
(Date:11/25/2009)...f., Nov. 25 ChemoCentryx, Inc., ...om the Company,s PROTECT-1 (the Prospective Random...ial) of Traficet-EN(TM) (CCX282-B) in patients wit...clinical efficacy with a favorable safety and tole... of clinical efficacy in the reduction of disease ...
(Date:11/24/2009)...24 ,, WHAT: Rom Houbens, a Be...s following an auto accident, was actually fully c...bject of a Good Morning America segment. The Dyna...te how people with Locked-in Syndrome and other co...od Morning America -- Tuesday, November 24 avail...
Breaking Medicine Technology:iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 6DynaVox EyeMax Featured in Good Morning America Segment About Man Thought To Be in Coma for 23 Years 2United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 54927 1United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 54927 2United Fresh to Feature Salad Bar at Capitol Hill Event to Advocate National School Salad Bar Policy 54927 3AMDL Inc Announces Second Quarter 2009 Financial Results 54924 1AMDL Inc Announces Second Quarter 2009 Financial Results 54924 2AMDL Inc Announces Second Quarter 2009 Financial Results 54924 3AMDL Inc Announces Second Quarter 2009 Financial Results 54924 4AMDL Inc Announces Second Quarter 2009 Financial Results 54924 5AMDL Inc Announces Second Quarter 2009 Financial Results 54924 6AMDL Inc Announces Second Quarter 2009 Financial Results 54924 7Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 1Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 2Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 3Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 4Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 5Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 6Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 7Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 8Results In The New England Journal Of Medicine Confirm Novartis Drug Femara 28R 29 Is Superior To Tamoxifen After Breast Cancer Surgery 4872 9
...echnology has enabled more and more laboratory tes... the central laboratory is hardly threatened with ...um and large labs are busier than ever before, and...rd reliability and ability to handle very large vo... position in the clinical landscape. , ,This i...
...nza infections in this country cause more than 114...Among healthy adults, bronchitis and pneumonia are...a and pneumonia are the sixth leading cause of dea... dangerous in elderly and immunocompromised people...a strains are serious illnesses in any patient. Pr...
Other Medicine Technology:When Volume Matters, Immunoassay Systems Deliver 2When Volume Matters, Immunoassay Systems Deliver 3Fast, Accurate Influenza A/B Antigen Detection 2Fast, Accurate Influenza A/B Antigen Detection 3
(Date:11/28/2009)... Study finds gene variation believed to affect cir...(HealthDay News) -- New research suggests that an ...e a factor in the development of bipolar disorder ...amination of the genetic makeup of 152 children wi...ible to major mood swings, and 140 children withou...
(Date:11/27/2009)..., Biotech firm Replikins ...of the H1N1 virus genomic data. It shows that the...of 3.7 (s.d. 4.5) during the virus,s current outbr...levels this week of 2.0 (s.d. 0.1). The H1N1 infec... Boston (PRWEB) November 27, 200...
(Date:11/27/2009)..., , NEUILLY-SUR-SEINE, France, Nov. 27 ...American professional cycling team dedicated to et...of cycling champions, announced today that it will...of Transitions Optical as a new sponsor of the tea...facturer of adaptive eyewear, offering the most ad...
(Date:11/27/2009)... Soaring rates to bring unprecedented medical, eco..., Nov. 27 (HealthDay News) -- The number of people... double over the next 25 years, a new study predic...ut 44.1 million people with the disease, up from 2...t of treating people with diabetes will triple, th...
(Date:11/27/2009)..., Specialist manufacturer... products are saving millions of dollars by bringi...gn process. Increasing numbers of pro-active medic...experts at the concept stage of their projects, en...isting design processes or potentially outdated te...
Breaking Medicine News(10 mins):Health News:Bipolar Disorder May Be Tied to Body Clock 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 2Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 3Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 4Health News:Lethality of H1N1 Virus Drops to "Non-Epidemic Resting Levels" in Current Cycle; Virus' Infectivity Remains Increased 5Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4
...search Funding to Prevent Setbacks in the Fight Ag...rch 16 With thousands of Americans losing health ...warns lawmakers that recent progress in reducing t...n, American Heart Association leadership outlined ...
...s safe and effective against heart attack in men, ...thDay News) -- Amid the continuing debate over who...ease, and at what dose, U.S. experts have revised ... dosage has long been discussed because aspirin ca...
... us the nation is getting fatter, and that obesity...story, according to one University of Houston soci...been a shift in body weight over the years, assist...an says. And the use of the Body Mass Index, which...
...ISCO, Calif., March 16 Poniard Pharmaceuticals, I... focused on oncology, today announced that its aud...d December 31, 2008, included in the Company,s Ann...This announcement is required by Nasdaq Marketplac...
...ose monitoring offers some men better quality of l...-- Refusing immediate treatment can be safe for me... monitored, new research finds. , The multi-cente...n a challenging question that faces patients and u...
...er of Health Systems Operating Retail-Based Care ,...onvenient care clinics across the country steadily...tems are exploring this relatively new health care...ally for non-profit health systems. , , The goal ...
Other Medicine News:Health News:American Heart Association Urges Congress to Accelerate Efforts to Enact Comprehensive Health Care Reform 2Health News:American Heart Association Urges Congress to Accelerate Efforts to Enact Comprehensive Health Care Reform 3Health News:American Heart Association Urges Congress to Accelerate Efforts to Enact Comprehensive Health Care Reform 4Health News:Experts Revise Guidelines on Daily Aspirin for Heart 2Health News:Experts Revise Guidelines on Daily Aspirin for Heart 3Health News:UH sociologist has different perspective on obesity 'epidemic' 2Health News:UH sociologist has different perspective on obesity 'epidemic' 3Health News:Poniard Pharmaceuticals Receives Going Concern Qualification 2Health News:'Watchful Waiting' Safe With Low-Risk Prostate Cancers 2Health News:Convenient Care Association Forms Round-Table for Health Systems Operating Convenient Care Clinics 2
Low Contrast Flip Chart with Lea Symbols
HOTV Distance Acuity Chart BCDI
Symbol 10' Test Chart BCS10
Binkhorst Hooked Cannula
Medicine Products: